MCF Advisors’s AstraZeneca AZN Stock Holding History

MCF Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14.2K	Hold	75	–	–	﹤0.01%	973
2026 Q1	$14.8K	Buy	75 +34	+83%	+$6.56K	﹤0.01%	884
2025 Q4	$7.54K	Buy	41 +38	+1,267%	+$6.67K	﹤0.01%	885
2025 Q3	$384	Buy	+3	New	+$454	﹤0.01%	927
2025 Q1	–	Sell	-7	Closed	-$852	–	922
2024 Q4	$852	Buy	+7	New	+$980	﹤0.01%	930
2023 Q3	–	Sell	-150	Closed	-$21.5K	–	924
2023 Q2	$21.5K	Hold	150	–	–	﹤0.01%	469
2023 Q1	$20.8K	Hold	150	–	–	﹤0.01%	470
2022 Q4	$20.3K	Hold	150	–	–	﹤0.01%	445
2022 Q3	$16K	Hold	150	–	–	﹤0.01%	489
2022 Q2	$20K	Buy	+150	New	+$19.7K	﹤0.01%	440

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

MCF Advisors's AZN Position: Q2 2026 in Review

MCF Advisors held its AstraZeneca (AZN) position steady in Q2 2026 at 75 shares worth $14.2K. The position accounts for ﹤0.01% of the portfolio, ranked #973.

MCF Advisors first reported a position in AZN in Q2 2022 and has held it in 10 quarters since. The position peaked at $21.5K in Q2 2023. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

MCF Advisors held 75 shares of AstraZeneca worth $14.2K as of Q2 2026.
MCF Advisors left its AstraZeneca share count unchanged in Q2 2026.
AstraZeneca made up ﹤0.01% of MCF Advisors's portfolio in Q2 2026, its #973 holding.
MCF Advisors first reported a position in AstraZeneca in Q2 2022 and has held it in 10 quarters since.
MCF Advisors's AstraZeneca position peaked at $21.5K in Q2 2023.
1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on MCF Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.